[Are new antibiotics in therapy of respiratory tract infections necessary?]

Area of Science:

• Microbiology
• Infectious Diseases
• Pharmacology

Background:

• Rising global antibacterial resistance in respiratory pathogens, particularly Streptococcus pneumoniae, poses a significant challenge.
• Penicillin-resistant S. pneumoniae strains exceed 80% in some regions, with macrolide and MLSb resistance also increasing.
• Documented quinolone resistance in Hong Kong and Spain highlights the evolving nature of antimicrobial resistance.

Purpose of the Study:

• To address the emerging problem of antibacterial resistance in respiratory tract infections.
• To emphasize the need for new antimicrobial agents alongside improved prescribing habits.
• To highlight the long-term strategies for preventing further resistance development.

Main Methods:

• Review of current trends in antibacterial resistance patterns.
• Analysis of the impact of prescribing habits on resistance.
• Discussion of strategies for combating antimicrobial resistance.

Main Results:

• Significant increases in resistance to penicillin, macrolides, MLSb, and quinolones among respiratory pathogens.
• Evidence that simply changing antibiotics without altering prescribing habits leads to new resistance issues.
• Identification of restrictive antibiotic prescription and adequate dosages as key long-term solutions.

Conclusions:

• Combating rising antibacterial resistance requires a dual approach: developing new antimicrobial drugs and fundamentally changing prescribing practices.
• Clinicians must adopt restrictive antibiotic prescribing and ensure adequate dosages to mitigate the long-term threat of resistance.
• Effective management of respiratory tract infections necessitates a comprehensive strategy addressing both therapeutic options and user behavior.